---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-041172"
form_type: "8-K"
ticker: "GALT"
cik: "0001133416"
company_name: "GALECTIN THERAPEUTICS INC"
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T19:27:41.227505+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Galectin reports Q3 2022 net loss $8.6M; NAVIGATE trial 88% enrolled

## Summary
- Net loss $8.6M ($0.14/sh) for Q3 2022, unchanged from Q3 2021.
- Cash $15.8M; plus $60M credit line; expects funding through Dec 2024.
- NAVIGATE trial: 279 of 315 patients randomized, 74 in screening; target full enrollment around end-2022.
- FDA allowed IND for belapectin + Keytruda in head and neck cancers.

## SEC filing metadata
- accession: 0001140361-22-041172
- form_type: 8-K
- ticker: GALT
- cik: 0001133416
- company_name: GALECTIN THERAPEUTICS INC
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133416/000114036122041172/0001140361-22-041172-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133416/000114036122041172/brhc10044046-8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-041172
- JSON: https://secwatch.observer/filing/0001140361-22-041172.json
- Plain text: https://secwatch.observer/filing/0001140361-22-041172.txt

## Key facts
- Earnings Releases
  GALECTIN THERAPEUTICS INC reported the three months ended September 30, 2022 results: net income $8.6 million, EPS ($0.14) per share.
  - Period: the three months ended September 30, 2022
  - Net income: $8.6 million
  - EPS: ($0.14) per share
  - Result: reported results
  source text: For the three months ended September 30, 2022, the Company reported a net loss applicable to common stockholders of $8.6 million, or ($0.14) per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1133416/000114036122041172/0001140361-22-041172-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.